

CITATION REPORT

List of articles citing

Additional baricitinib loading dose improves clinical outcome in COVID-19

DOI: 10.1515/med-2021-0010
Open Medicine (Poland), 2021, 16, 41-46.

Source: <https://exaly.com/paper-pdf/87227706/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Clinical Efficacy and Adverse Events of Baricitinib Treatment for Coronavirus Disease-2019 (COVID-19): A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> ,	1	0
19	Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh. <i>BMC Infectious Diseases</i> , 2021 , 21, 427	4	15
18	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , 2021 , 51, 1615-1627	6.1	13
17	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	13
16	Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?. <i>Journal of Infection</i> , 2021 , 83, e11-e13	18.9	4
15	The signal pathways and treatment of cytokine storm in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 255	21	84
14	Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2021 , 99, 108027	5.8	7
13	Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2021 ,	19.7	3
12	One-year Review of COVID-19 in the Arab World. <i>Qatar Medical Journal</i> , 2021 , 2021, 66	0.5	0
11	Inhibition of the JAK/STAT pathway with baricitinib reduces the multiple organ dysfunction caused by hemorrhagic shock in rats.		0
10	Treatment strategies of Covid-19. A rheumatology perspective.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	2
9	A Comprehensive Overview of Globally Approved JAK Inhibitors. <i>Pharmaceutics</i> , 2022 , 14, 1001	6.4	6
8	Janus kinase inhibitors for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	1
7	Currently available drugs for the treatment of Coronavirus-2. 2022 , 77-95		
6	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022 , 202, 115162	6	0
5	Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. 2022 , 3,		2
4	Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis.		2

- 3 Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. **2022**, 202, 106986 1
- 2 Baricitinib in the Treatment of COVID-19. 0
- 1 Use of baricitinib in treatment of COVID-19: a systematic review. 0